Peter Brust, October 23

SciLifeLab The Svedberg seminar series

Thursday, October 23


Peter Brust

Helmholtz-Zentrum Dresden Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Germany

Peter Brust is an expert in the following areas: Expression of transport systems at the blood-brain barrier, Pathophysiology of the dopaminergic system (asphyxia, experimental trauma), Imaging of the brain serotonergic and cholinergic system with positron emission tomography, Development of radioligands for neuroimaging of neurodegenerative diseases and Neuroimaging of traumatic brain injury.

Design of 18F-labelled radiopharmaceuticals for brain imaging

Imaging with positron emission tomography (PET) is widely used for early diagnosis and treatment follow-up of many brain diseases. PET uses probes (radiotracers) which are labeled with radionuclides of short half-lives, synthesized prior to the imaging studies. Fluorine-18 is a radionuclide that is routinely used in the radiolabeling of neuroreceptor ligands because of its favorable half-life of 109.8 min. The delivery of such PET-radiotracers into the brain provides images of transport, metabolic, and neurotransmission processes on the molecular level. This talk will focus on the strategy of radiotracer development. Successful radiotracer design provides molecular probes which not only are useful for imaging of human brain diseases, but also allow molecular neuroreceptor imaging studies in various small-animal models of disease, including genetically engineered animals. Furthermore, they provide powerful tools for in vivo pharmacology in pre-clinical drug development, to investigate pathophysiology, to discover drug candidates, and to evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo.


Host: Mats Larhed